Zydus Cadila gets tentative USFDA nod for Tofacitinib ER tablets

Zydus Cadila gets tentative USFDA nod for Tofacitinib ER tablets

82
Medicine
Picture: Pixabay

Last Updated on October 20, 2020 by The Health Master

Zydus Cadila has received tentative approval from the USFDA to market Tofacitinib Extended-Release Tablets, 11 mg (US RLD: Xeljanz XR Tablets).

It is recommended for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis (UC).

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 308 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.